The tumor microenvironment is a complex structure of cancer cells recruiting innate immune cells to protect the tumor and promote its growth. Disrupting this interplay is a potent tool for cancer therapies. Genagon pioneered a way to target macrophages and cancer cells and by disturbing the dynamic lifecycle of proteins within the tumor microenvironment. Targeting harmful tumor-associated macrophages directly paves the way for novel ways to target and eradicate tumors.
Genagon Therapeutics
Genagon Therapeutics’s drug development is based on discoveries of unstudied proteins and their life cycles in innate immune cells.
